Jerome Ritz MD

Hematologic Oncology

Professor of Medicine, Dana-Farber Cancer Institute

450 Brookline AveM530, Dana-Farber Cancer InstituteBoston, MA 02215
Phone+1 617-632-3465
Fax+1 617-632-5167

Dr. Ritz is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ritz's full profile Already have an account?

Summary

Dr. Jerome Ritz is a hematologist based in Boston, MA, specializing in hematologic oncology. He completed his medical education at Chicago Medical School and further specialized with a fellowship in Hematology and Medical Oncology at Beth Israel Deaconess Medical Center, following a residency in Internal Medicine at University of Wisconsin Hospitals and Clinics. He is currently a Professor of Medicine at Dana-Farber Cancer Institute and Harvard Medical School. Dr. Ritz is experienced in hematologic oncology, stem cell transplantation, tumor immunology, leukemia, and cell therapy. He has authored over 500 peer-reviewed publications in leading journals including New England Journal of Medicine, Nature Medicine, Science Translational Medicine, Journal of Clinical Oncology and Blood. He is an elected member of the American Society for Clinical Investigation and Association of American Physicians and is a Fellow of the American Society of Transplantation and Cellular Therapy.

Education & Training

University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1972 - 1975
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 1972
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MA State Medical License 1976 - 2027
CO State Medical License 1975 - 1980
WI State Medical License 1973 - 1979
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Elected Member Association of American Physicians, 2021
CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2017

Publications & Presentations

PubMed

Long-term stability of posttranscriptional genetic silencing of BCL11A using a shmiR vector in sickle cell disease.
Erica B Esrick, Leslie Lehmann, Amy Federico, Helene Vincon, Boya Liu
Blood. 2026-08-20
Venetoclax-augmented RIC allogeneic HCT with PTCy-based GVHD prophylaxis and venetoclax/azacitidine maintenance for poor risk MDS and AML.
H Moses Murdock, Kyle Hebert, Mahasweta Gooptu, Roman Shapiro, Gregory Abel
Transplantation and Cellular Therapy. 2026-08-19
2 citations
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.
Omar Nadeem, David M Cordas Dos Santos, Sarah Nikiforow, Anna Bosch-Vilaseca, Elizabeth O'Donnell
Nature Medicine. 2026-07-01

Journal Articles

Small-Molecule BCL6 Inhibitor Effectively Treats Mice with Non-Sclerodermatous Chronic Graft-Versus-Host Disease
Joseph H Antin, Leo Luznik, John Koreth, Ivan Maillard, Robert J Soiffer, Jonathan S Serody, Jerome Ritz, Blood
Immunophenotyping of Pediatric Brain Tumors: Correlating Immune Infiltrate with Histology, Mutational Load, and Survival and Assessing Clonal T Cell Response
Isaac H Solomon, Mark W Kieran, Gabriel K Griffin, Pratiti Bandopadhayay, Jerome Ritz, Ashley S Plant, Keith L Ligon, Glenn Dranoff, Journal of Neuro-Oncology

Abstracts/Posters

Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizu...
Jerome Ritz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Graft Failure after Haploidentical Hematopoietic Stem Cell Transplantation
Jerome Ritz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Development of HHV-6-Specific Immunity after Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis and Regeneration of CD4+ T Cells
Jerome Ritz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Stem Cell Therapy Repairs Corneal Damage in TrialMarch 6th, 2025
Lifechanging Stem Cell Treatment Repairs Irreversible Corneal DamageMarch 6th, 2025
HMN 2025: How Novel Stem Cell Remedy Repairs ‘Irreversible’ Corneal Harm in Scientific TrialMarch 5th, 2025

Grant Support

Epigenetic Profiling of circulating cell-free DNA for the Monitoring of Graft-Versus-Host Disease after Hematopoietic Cell TransplantationCORNELL UNIVERSITY2020–2025